Literature DB >> 21205608

[The potential role of heat shock proteins in the treatment of ovarian cancer].

Zoltán Langmár1, Gábor Vleskó.   

Abstract

Ovarian carcinoma has the highest mortality among gynecologic cancers. Most of the patients are sensitive to the first-line platinum-based combined chemotherapy and they will present a complete response, but most of them will relapse within 24 months. The resistance to chemotherapy is a great therapeutic challenge. Recent figures show that heat shock proteins play a significant role in certain mechanisms of carcinogenesis and are involved in the resistance to anticancer drug therapy. Our paper gives a summary of recent data concerning heat shock proteins in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205608     DOI: 10.1556/OH.2011.29024

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  2 in total

1.  Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium.

Authors:  Stefanie Aust; Anna Bachmayr-Heyda; Petra Pateisky; Dan Tong; Silvia Darb-Esfahani; Carsten Denkert; Radoslav Chekerov; Jalid Sehouli; Sven Mahner; Toon Van Gorp; Ignace Vergote; Paul Speiser; Reinhard Horvat; Robert Zeillinger; Dietmar Pils
Journal:  Mol Cancer       Date:  2012-09-14       Impact factor: 27.401

2.  CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer.

Authors:  Yang Zeng; Binghao Li; Tao Li; Wei Liu; Chongzhao Ran; Richard T Penson; Mark C Poznansky; Yanan Du; Huabiao Chen
Journal:  Oncotarget       Date:  2019-07-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.